References

Electronic Medicines Compendium. Praluent 150 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SPC) - (eMC). 2020a. https://www.medicines.org.uk/emc/product/8093/smpc (accessed 15 January 2020)

Electronic Medicines Compendium. Reptha - Summary of Product Characteristics (SPC) - (eMC). 2020b. https://www.medicines.org.uk/emc/product/6962 (accessed 15 January 2020)

Electronic Medicines Compendium. Forsteo - Summary of Product Characteristics (SPC) - (eMC). 2020c. https://www.medicines.org.uk/emc/product/2215/smpc (accessed 15 January 2020)

Electronic Medicines Compendium. Xolair - Summary of Product Characteristics (SPC) - (eMC). 2020d. https://www.medicines.org.uk/emc/product/4725/smpc (accessed 18 May 2011)

Food and Drug Administration. What Are “Biologics” Questions and Answers. 2019. https://www.fda.gov/about-fda/about-center-biologics-evaluation-and-research-cber/what-are-biologics-questions-and-answers (accessed 17 June 2021)

gov.uk. Guidance: Contraindications and special considerations: the green book, chapter 6. 2017. https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6 (accessed 26 February 2021)

gov.uk. Yellow fever vaccine (Stamaril) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed and those 60 years and older. 2019. https://www.gov.uk/drug-safety-update/yellow-fever-vaccine-stamaril-and-fatal-adverse-reactions-extreme-caution-needed-in-people-who-may-be-immunosuppressed-and-those-60-years-and-older (accessed 17 June 2021)

gov.uk. Regulatory approval of COVID-19 Vaccine Moderna. 2021a. https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna (accessed March 1 2021)

gov.uk. Moderna vaccine becomes third COVID-19 vaccine approved by UK regulator. 2021b. https://www.gov.uk/government/news/moderna-vaccine-becomes-third-covid-19-vaccine-approved-by-uk-regulator (accessed March 1 2021)

gov.uk. Guidance on shielding and protecting people defined on medical grounds as extremely vulnerable from COVID-19. 2021c. https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19 (accessed 26 February 2021)

Greater Manchester Medicines Management Group. Current Adult Red Amber Green (RAG) List. 2021. http://gmmmg.nhs.uk/html/rag_dnp_adult.php (accessed 25 May 2021)

Hejanes KR, Ransohoff TC Chapter 50 - Chemistry, Manufacture and Control. Elsevier.Amsterdam: Biopharmaceutical Processing : Development, Design, and Implementation of Manufacturing Processes. Elsevier; 2018

Drug Ther Bull. 2016; 54:(4)45-48 https://doi.org/10.1136/dtb.2016.4.0396

Mantaj J, Vllasaliu D Recent advances in the oral delivery of biologics. The Pharmaceutical Journal. 2020; 304:(7933) https://doi.org/10.1211/pj.2020.20207374

NHS England. NHS cuts medicines costs by three quarters of a billion pounds. 2019. https://www.england.nhs.uk/2019/08/nhs-cuts-medicines-costs-by-three-quarters-of-a-billion-pounds/ (accessed 26 May 2021)

NHS England. Biosimilar medicines. 2021. http://www.englandnhsuk (accessed 25 May 2021)

Patient Safety Network. Alert fatigue. 2019. https://psnet.ahrq.gov/primer/alert-fatigue# (accessed 25 May 2021)

Payne R The rising tide of biological therapy. Prescriber. 2019; 30:(3)4-4 https://doi.org/10.1002/psb.1744

Queensland Department of Health. Medicines/pharmaceuticals of animal origin. 2020. https://www.health.qld.gov.au/__data/assets/pdf_file/0024/147507/qh-gdl-954.pdf (accessed 1 March 2021)

The National Institute for Health and Care Excellence. Overview | Dimethyl fumarate for treating relapsing remitting multiple sclerosis | Guidance | NICE. 2014. https://www.nice.org.uk/guidance/ta32 (acccessed 25 May 2021)

The National Institute for Health and Care Excellence. Overview | Dimethyl fumarate for treating moderate to severe plaque psoriasis | Guidance | NICE. 2017. https://www.nice.org.uk/guidance/ta47 (accessed 26 February 2021)

The National Institute for Health and Care Excellence. COVID-19 rapid evidence summary: Sarilumab for COVID-19. 2021. https://www.nice.org.uk/advice/es34/chapter/Product-overview (accessed 9 February 2021)

The Supreme Court (UKSC). Montgomery (Appellant) v Lanarkshire Health Board (Respondent) (Scotland). 2015. https://www.supremecourt.uk/cases/docs/uksc-2013-0136-press-summary.pdf (accessed 1 March 2021)

Veiga VC, Prats JAGG, Farias DLC Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021; https://doi.org/10.1136/bmj.n84

Number of vegans Great Britain 2019. 2020. https://www.statista.com/statistics/1062104/number-of-vegans-in-great-britain/#statisticContaine (accessed 1 March 2021)

Medicines reconciliation of biologics on a primary care clinical system

02 July 2021
Volume 3 · Issue 7

Abstract

With increasing number of biologics gaining approval from the National Institute for Health and Care Excellence for a wide variety of both cancer and non-cancer clinical indications in secondary care, the need for accurate medicines reconciliation in primary care also increases. The risk of patient harm from incomplete medicines reconciliation is a consideration, particularly when patient data is transferred from a secondary care setting to a primary care setting. As part of a prescribing quality improvement project, a list of biologics prescribed by secondary care providers were reconciled on to patients' primary care clinical systems (EMIS) by clinical pharmacists and pharmacy technicians at a Clinical Commissioning Groups. Patients were identified by cross-referencing high-cost drug reports with clinical diagnostic codes (a mixture of READ codes and SNOMED-CT terms) on primary care clinical systems. In total, 192 medicines were reconciled safely on the relevant patients' notes across 16 different GP practices A further 81 medicines had already been reconciled at the start of the quality improvement project. The purpose of this article is three-fold; to expand the awareness of biologics in the context of medicines optimisation in the primary care arena, to discuss medicines reconciliations of biologics in primary care, including the role(s) of pharmacy professionals, and to discuss the wider implications of prescribing biologics in the light of ethical considerations such as veganism.

In the broadest sense of the word, ‘biologics’ are not anything new at all. Biologics have been defined by the American Food and Drug Agency (FDA, 2019) as being ‘composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities such as cells and tissues. Biologics are isolated from a variety of natural sources – human, animal, or microorganism – and may be produced by biotechnology methods and other cutting-edge technologies’. Using this definition products such as insulins, erthyropoetins and pancreatin, which are both well-established and frequently prescribed medicines, can be included. For the purposes of this article however, the term ‘biologics’ will refer to a paraphrased version of the latter part of the FDA (2019) definition ie ‘organic based medicines manufactured using new technology, which includes biotechnology’. The term ‘new’ in this context is highly subjective, given the rate of advancements in medicine, particularly in this 21st century. What might be new at the time of writing this article may not be new by the time this article is read. That said, ‘biologics’ (using this paraphrased definition) includes (but is not limited to) the following:

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month